Biological activity of immunostimulatory CpG DNA motifs in domestic animals

被引:99
作者
Mutwiri, G
Pontarollo, R
Babiuk, S
Griebel, P
Littel-van den Hurk, SV
Mena, A
Tsang, C
Alcon, V
Nichani, A
Ioannou, X
Gomis, S
Townsend, H
Hecker, R
Potter, A
Babiuk, LA
机构
[1] Univ Saskatchewan, Vet Infect Dis Org, Saskatoon, SK S7N 5E3, Canada
[2] QIAGEN GmbH, D-40724 Hilden, Germany
关键词
CpG DNA; oligodeoxynucleotides; immunostimulation; adjuvants; animals;
D O I
10.1016/S0165-2427(02)00246-5
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Bacterial DNA contains a much higher frequency of CpG dinucleotides than are present in mammalian DNA. Furthermore, bacterial CpG dinucleotides are often not methylated. It is thought that these two features in combination with specific flanking bases constitute a CpG motif that is recognized as a "danger" signal by the innate immune system of mammals and therefore an immune response is induced when these motifs are encountered. These immunostimulatory activities of bacterial CpG DNA can also be achieved with synthetic CpG oligodeoxynucleotides (ODN). Recognition of CpG motifs by the innate immune system requires engagement of Toll-like receptor 9 (TLR-9), which induces cell signaling and subsequently triggers a pro-inflammatory cytokine response and a predominantly Th1-type immune response. CpG ODN-induced innate and adaptive immune responses can result in protection in various mouse models of disease. Based on these observations, clinical trials are currently underway in humans to evaluate CpG ODN therapies for cancer, allergy and infectious disease. However, potential applications for immunostimulatory CpG ODN in species of veterinary importance are just being explored. In this review, we will highlight what is presently known about the immunostimulatory effects of CpG ODN in domestic animals. (C) 2002 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:89 / 103
页数:15
相关论文
共 114 条
[1]  
Agrewala JN, 1996, CYTOKINES MOL THER, V2, P59
[2]   ADJUVANTS - CURRENT STATUS, CLINICAL PERSPECTIVES AND FUTURE-PROSPECTS (REPRINTED FROM TRENDS IN PHARMACOLOGICAL SCIENCES, VOL 14, PG 174-178, 1993) [J].
AUDIBERT, FM ;
LISE, LD .
IMMUNOLOGY TODAY, 1993, 14 (06) :281-284
[3]  
Auf G, 2001, CLIN CANCER RES, V7, P3540
[4]   Immunization of animals: from DNA to the dinner plate [J].
Babiuk, LA ;
van Drunen Littel-van den Hurk, S ;
Babiuk, SL .
VETERINARY IMMUNOLOGY AND IMMUNOPATHOLOGY, 1999, 72 (1-2) :189-202
[5]   Intranasal immunization with liposome-formulated Yersinia pestis vaccine enhances mucosal immune responses [J].
Baca-Estrada, ME ;
Foldvari, M ;
Snider, M ;
Harding, K ;
Kournikakis, B ;
Babiuk, LA ;
Griebel, P .
VACCINE, 2000, 18 (21) :2203-2211
[6]   Divergent therapeutic and immunologic effects of oligodeoxynucleotides with distinct CpG motifs [J].
Ballas, ZK ;
Krieg, AM ;
Warren, T ;
Rasmussen, W ;
Davis, HL ;
Waldschmidt, M ;
Weiner, GJ .
JOURNAL OF IMMUNOLOGY, 2001, 167 (09) :4878-4886
[7]  
Ballas ZK, 1996, J IMMUNOL, V157, P1840
[8]   Adamantylamide dipeptide as effective immunoadjuvant in rabbits and mice [J].
Becker, PD ;
Corral, RS ;
Guzmán, CA ;
Grinstein, S .
VACCINE, 2001, 19 (32) :4603-4609
[9]   CPG-RICH ISLANDS AND THE FUNCTION OF DNA METHYLATION [J].
BIRD, AP .
NATURE, 1986, 321 (6067) :209-213
[10]   DNA and a CpG oligonucleotide derived from Babesia bovis are mitogenic for bovine B cells [J].
Brown, WC ;
Estes, DM ;
Chantler, SE ;
Kegerreis, KA ;
Suarez, CE .
INFECTION AND IMMUNITY, 1998, 66 (11) :5423-5432